Skip to content

Reentry Assist (R-Assist)

Reentry-Assist App Development for Individuals With Addiction and Mental Illness

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06980233
Acronym
R-Assist
Enrollment
38
Registered
2025-05-20
Start date
2025-06-01
Completion date
2026-04-30
Last updated
2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Criminal Recidivism, Mental Health Disorder, Substance Use Disorder (SUD)

Keywords

substance use disorder, mental health, criminal-legal involvement

Brief summary

This project will aim to develop and pilot test, R-Assist, a mobile health application to support individuals with co-occurring substance use and mental health disorders (COD) in their recovery, who have recently released from a participating Massachusetts jail.

Detailed description

This Phase I project will develop and test an mHealth app called R-Assist among individuals with COD recently released from a Massachusetts jail. R-Assist will offer four core features, including linkages to community resources via the resource locator, on demand, tailored self-help materials, and self-management/organizational tools. The following two Aims will be tested: Aim 1. R-Assist software and content prototype development. The 4 R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) social determinants of health (SDOH) resource finder; and 4) a dashboard to track R-Assist engagement. Aim 2. A successive cohort study of the R-Assist prototype with participants who have recently left jail (N = 38). This will include three successive field focus group cohorts with 18 participants, followed by a small open pilot with 20 participants. This project's four milestones will be executed in preparation for a larger Phase II trial. * Milestone 1 (Months 1-5): R-Assist App Development and Interface Designs o No human subjects involvement * Milestone 2 (Months 6-7): Initial Evaluation/Refinement of R-Assist o To recruit N=18 individuals for this Milestone * Milestone 3 (Months 8-10): Open Pilot of R-Assist o To recruit recruit N=20 individuals for this Milestone * Milestone 4 (Months 11-12): Product Refinement Prior to Phase II and Dissemination o No human subjects involvement

Interventions

BEHAVIORALreentry assistance mobile health app

R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session MISSION-CJ self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) SDOH resource finder; and 4) a dashboard to track R-Assist engagement.

Sponsors

Meaningful Measurement, Inc
Lead SponsorINDUSTRY
National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Massachusetts, Worcester
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session MISSION-CJ self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) SDOH resource finder; and 4) a dashboard to track R-Assist engagement.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have been released from the participating jail within the past 150 days * Own a smartphone (Android or iOS; 90% met this criterion in our prior studies) * Have COD: any substance use disorder (we will allow poly-substance use disorders) and a co-occurring mental health disorder (depression, anxiety, trauma related disorders, bipolar, and/or schizophrenia) * Consent to R-Assist app use observation and e-tracking * Consent to audio recording during interviews and focus groups.

Exclusion criteria

* Acutely suicidal, homicidal, or psychotic * Unable to provide informed consent * Individuals released with monitoring devices or individuals involved in drug treatment courts

Design outcomes

Primary

MeasureTime frameDescription
App usageFrom enrollment for 1.5 months during the open pilotTotal time engaged in app will be tracked daily during open pilot period. Additionally, engagement and time with each feature will be tracked
System Usability Scale (SUS)From enrollment for 1.5 months during the open pilotOverall score will be computed, indicating overall usability Score ranges from 0-100 (0-64=not acceptable, 65-84=acceptable, and 85, 100=excellent.
Mobile Application Rating Scale (MARS)From enrollment for 1.5 months during the open pilotOverall score will be computed, indicating overall acceptability, as well as score for each of the four dimensions. The rating scale assesses app quality on four dimensions (1. Engagement, 2. Functionality, 3. Aesthetics, and 4. Information). All items are rated on 5-point scale from "1=inadequate" to "5=excellent"
Composite International Diagnostic Instrument for DSM-IV: Social determinants of health (SDOH) linkagesFrom enrollment for 1.5 months during the open pilotSDOH needs (e.g., housing instability, food insecurity, NA/AA/ other recovery linkages) will be assessed and the App will track all referrals and SDOH linkages made. Percent of linkages made to needed SDOH services will be examined.
Composite International Diagnostic Instrument for DSM-IV: Substance Use DisorderFrom enrollment for 1.5 months during the open pilotSubstance use disorder symptoms will be tracked daily during the open pilot period.
Composite International Diagnostic Instrument for DSM-IV: Mental HealthFrom enrollment for 1.5 months during the open pilotMental health symptoms will be tracked daily during the open pilot period.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDavid Smelson, PsyD

University of Massachusetts Chan Medical School

PRINCIPAL_INVESTIGATORDonna Surges Tatum, PhD

Meaningful Measurement, LLC

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026